StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.05−0.07 (-0.98%)

Close on Nov 20, 2026Market cap $363.92MP/E 13.6Yield –

Puma Biotechnology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Puma Biotechnology's pe ratio was 15.5× on Nov 11, 2026, against 6.8× a year earlier. Over the last 4 years it ranged from 4.0× to 58.8×, with a median of 11.8×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.5×+7.5
2025Dec 31, 20258.0×+1.7
2024Dec 31, 20246.4×−47.8
2023Dec 29, 202354.1×+34.9
2022Dec 30, 202219.2×–

More Puma Biotechnology figures

See a number that looks wrong?